Assessment of melanoma precision prevention materials incorporating MC1R genetic risk information

Transl Behav Med. 2022 May 26;12(5):683-687. doi: 10.1093/tbm/ibac034.

Abstract

Few studies have examined cognitive responses to mailed precision prevention materials. MC1R is a robust, well-described melanoma susceptibility marker. The purpose was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk. Non-Hispanic White participants (n = 1134) enrolled in a randomized controlled trial received either precision prevention materials incorporating MC1R genetic risk (higher/average) or generic prevention (standard) materials. Six months after baseline, 808 (71.3%) participants reported on the amount of prevention materials read (5-point scale); believability and clarity of materials; intention to change preventive behaviors (7-point Likert scale); and recall of their MC1R genetic risk. Comparisons were conducted using Kruskal-Wallis and chi-squared tests. Overall, participants read most to all (Mdn = 4, IQR = 2) of the prevention materials, reported high believability (Mdn = 7, IQR = 1) and clarity (Mdn = 7, IQR = 1), and moderate intention to change preventive behaviors (Mdn = 5, IQR = 2). Higher-risk participants reported slightly less clarity (Mdn = 6, IQR = 2) than either average-risk (Mdn = 6, IQR = 1, p = 2.50 × 10-3) or standard participants (Mdn = 7, IQR = 1, p = 2.30 × 10-5); and slightly less believability (Mdn = 6, IQR = 1) than standard participants (Mdn = 7, IQR = 1, p = .005). Higher-risk participants were 2.21 times as likely (95% CI = 1.43-3.43) to misremember or forget their risk compared to average-risk participants; misremembering was observed only among higher-risk participants (14%). Mailed precision prevention information were mostly read, highly believable and clear, and resulted in moderate levels of intention to change sun protection behaviors, bolstering the feasibility of population-level precision prevention. Defensive reactions may explain lower clarity, believability, and higher incorrect risk recall among higher-risk participants.

Trial registration: ClinicalTrials.gov NCT03509467.

Keywords: Genetic testing; MC1R; Melanoma; Precision prevention; Public health genomics.

Plain language summary

Precision prevention uses an individual’s genetics, environment, and/or lifestyle to promote prevention behaviors. However, if materials incorporating precision prevention information are not easily accessible, individuals may misinterpret or distrust findings. Few studies have examined participant-reported believability and clarity of mailed precision prevention materials, how much they read, and whether they intend to change preventive behaviors. We assessed genetic risk for melanoma by determining DNA variation at the MC1R gene, a known melanoma risk marker. Participants were mailed either precision prevention materials conveying their MC1R genetic risk or generic (without genetic risk information) prevention materials. Overall, participants read most of the materials, gave high believability and clarity scores, and reported moderate levels of intention to change preventive behavior. However, participants at higher genetic risk had slightly lower believability and clarity scores than the generic group and were more likely to forget or misremember their genetic risk than participants at average genetic risk. Among participants who correctly recalled their genetic risk, differences in believability diminished, while differences in clarity remained. We conclude that precision prevention materials are highly believable and clear, but additional strategies may be necessary to maximize believability, clarity, and risk recall for individuals at a higher genetic risk.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Intention
  • Melanoma* / genetics
  • Melanoma* / prevention & control
  • Receptor, Melanocortin, Type 1 / genetics*
  • Risk Factors

Substances

  • MC1R protein, human
  • Receptor, Melanocortin, Type 1

Associated data

  • ClinicalTrials.gov/NCT03509467